Article Text

PDF
AB0692 Effects of intravenous golimumab on patient-reported outcomes in active ankylosing spondylitis: 28-week results of the phase III go-alive trial
  1. JD Reveille1,
  2. A Deodhar2,
  3. EK Chan3,
  4. S Peterson4,
  5. N Li4,
  6. E Hsia4,5,
  7. L Kim4,
  8. KH Lo4,
  9. DD Harrison4,
  10. C Han6
  1. 1University of Texas Health Sciences Center, Houston
  2. 2Oregon Health & Science University, Portland
  3. 3Janssen Global Services, LLC, Raritan
  4. 4Janssen R&D, LLC, Spring House
  5. 5University of Pennsylvania School of Medicine, Philadelphia
  6. 6Janssen Global Services, LLC, Malvern, United States

Abstract

Objectives To evaluate patient-reported outcomes (PRO) of physical functioning, mental health functioning, health state, and health-related quality of life (HRQoL) in patients (pts) w/active Ankylosing Spondylitis (AS) treated w/intravenously administered (IV) golimumab (GLM), an anti-TNFα monoclonal antibody.

Methods GO-ALIVE is a Phase 3, multicenter, randomized, double-blind, placebo-controlled trial. Pts (aged ≥18 years) had a diagnosis of definite AS (per modified New York criteria) and BASDAI ≥4, total back pain visual analogue scale ≥4, and CRP ≥0.3mg/dL. At baseline, 208 pts were randomized either to IV GLM 2mg/kg (N=105) at Wks 0, 4, and every 8 wks or placebo (PBO, N=103) at Wks 0, 4, and 12, w/crossover to GLM at Wk 16.

Three PRO instruments were included: 1) SF-36, a generic instrument designed to measure physical & mental health functioning, 2) EQ-5D visual analogue scale (VAS), a generic measure of current health state & 3) Ankylosing Spondylitis Quality of Life (ASQoL) questionnaire, a disease-specific instrument designed to measure the impact of AS on HRQoL. The scores for SF-36 range from 0–100 w/higher scores indicating better functioning. It has Physical (PCS) and Mental Component Summary (MCS) and eight subscales (physical functioning, role-physical, body pain, general health, vitality, social functioning, role-emotional, & mental health). EQ-5D has a scale of 0–100 (0=worst health you can imagine to 100=best health you can imagine). ASQoL assesses sleep, mood, motivation, ability to cope, activities of daily living, independence, relationships, & social life in pts w/AS. The scores range from 0–18 w/higher scores indicating worse HRQoL. Unadjusted p-values of least square mean differences (LSMD) between treatment groups were based on analysis of covariance (ANCOVA) controlling for prior anti-TNF therapy.

Results Table 1 summarizes the mean changes from baseline at Wks 8, 16, & 28. Improvements from baseline in SF-36 PCS & MCS were greater in the GLM group than PBO at Wk 8 (6.83 vs. 2.07, p<0.001; 5.56 vs. 1.67, p=0.006, respectively) and maintained through Wk 16 (8.52 vs. 2.87, p<0.001; 6.47 vs. 0.84, p<0.001, respectively). Improvements in all SF-36 subscales were observed in the GLM group at Wks 8 & 16 compared to PBO (p<0.01, with the exception of the role-emotional subscale [p=0.058]). The percentage of pts achieving clinically meaningful change (5 points or greater) in SF-36 PCS & MCS were higher in GLM than PBO in Wks 8 & 16 (PCS: 58.1 vs. 27.2, 67.6 vs. 35.9, respectively; MCS: 48.6 vs. 34.0, 54.3 vs. 29.1, respectively; p<0.05 for all). Mean EQ-5D VAS improvements were greater (p<0.001) in GLM than PBO at Wks 8 & 16 (17.61 vs. 6.63, 20.32 vs. 4.79, respectively). Greater improvements in ASQoL were observed in GLM compared to PBO at Wks 8 & 16 (-4.5 vs. -1.5, p<0.001, -5.4 vs. -1.8, p<0.001, respectively). By Wk 28, after PBO crossed-over to GLM, improvement in PCS, MCS, EQ-5D VAS, & ASQoL were similar between the two treatment arms.

Conclusions Adult pts w/active AS treated w/IV GLM showed marked improvements in physical functioning, mental health functioning, health state, & HRQoL.

Disclosure of Interest J. Reveille Grant/research support from: Janssen Scientific Affairs, LLC., A. Deodhar Grant/research support from: Janssen, Amgen, Abbvie, GSK, Eli Lilly, Novartis, Pfizer, UCB, Consultant for: Janssen, Eli Lilly, Novartis, Pfizer, UCB, E. Chan Employee of: Janssen Global Services, LLC, S. Peterson Employee of: Janssen R&D, LLC, N. Li Employee of: Janssen R&D, LLC, E. Hsia Employee of: Janssen R&D, LLC, L. Kim Employee of: Janssen R&D, LLC, K. H. Lo Employee of: Janssen R&D, LLC, D. Harrison Employee of: Janssen R&D, LLC, C. Han Employee of: Janssen Global Services, LLC

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.